Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
humans (16) 16
female (13) 13
middle aged (13) 13
male (12) 12
aged (9) 9
adult (8) 8
clinical trials (6) 6
treatment outcome (6) 6
hepatitis c, chronic - drug therapy (5) 5
antiviral agents - therapeutic use (4) 4
benzimidazoles - therapeutic use (4) 4
drug therapy, combination (4) 4
interferon (4) 4
oligopeptides - therapeutic use (4) 4
patients (4) 4
peripheral vascular disease (4) 4
research (4) 4
therapy (4) 4
thiazoles - therapeutic use (4) 4
young adult (4) 4
abridged index medicus (3) 3
aged, 80 and over (3) 3
antiviral agents - adverse effects (3) 3
benzimidazoles - adverse effects (3) 3
bi 207127 (3) 3
biomarkers (3) 3
brain ischemia - epidemiology (3) 3
drug therapy (3) 3
efficacy (3) 3
extended-release dipyridamole (3) 3
gastroenterology & hepatology (3) 3
gastroenterology and hepatology (3) 3
hepacivirus - genetics (3) 3
hepatitis (3) 3
hepatitis c (3) 3
hepatitis c, chronic - genetics (3) 3
hepatitis c, chronic - virology (3) 3
hepatitis-c (3) 3
hiv (3) 3
hiv-1-infected patients (3) 3
oligopeptides - adverse effects (3) 3
pharmacology & pharmacy (3) 3
protease inhibitor (3) 3
protease inhibitors (3) 3
recurrence (3) 3
ribavirin (3) 3
risk (3) 3
risk factors (3) 3
safety (3) 3
stroke - epidemiology (3) 3
studies (3) 3
telmisartan (3) 3
thiazoles - adverse effects (3) 3
acrylates - adverse effects (2) 2
acrylates - therapeutic use (2) 2
adolescent (2) 2
analysis (2) 2
angiotensin-converting enzyme inhibitors - therapeutic use (2) 2
antineoplastic agents - therapeutic use (2) 2
antiviral agents (2) 2
autoantibodies (2) 2
azepines - adverse effects (2) 2
azepines - blood (2) 2
azepines - pharmacokinetics (2) 2
b-cells (2) 2
benzimidazoles - administration & dosage (2) 2
benzoates - therapeutic use (2) 2
bioavailability (2) 2
biopsy (2) 2
brain ischemia - complications (2) 2
brain ischemia - prevention & control (2) 2
care and treatment (2) 2
clinical neurology (2) 2
clopidogrel (2) 2
combination (2) 2
dendritic cells (2) 2
disease (2) 2
dosage and administration (2) 2
double-blind (2) 2
double-blind method (2) 2
drug dosages (2) 2
drug interactions (2) 2
endoscopy (2) 2
follow-up studies (2) 2
gastroenterology (2) 2
genotype (2) 2
genotype & phenotype (2) 2
genotypes (2) 2
half-life (2) 2
hepacivirus - drug effects (2) 2
hepatitis c virus (2) 2
hiv protease inhibitors - administration & dosage (2) 2
hiv protease inhibitors - adverse effects (2) 2
hiv protease inhibitors - blood (2) 2
hiv protease inhibitors - pharmacokinetics (2) 2
human immunodeficiency virus--hiv (2) 2
immunodeficiency-virus-infection (2) 2
infection (2) 2
infections (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Faldaprevir and Deleobuvir for HCV Genotype 1 Infection
by Zeuzem, Stefan and Soriano, Vincent and Asselah, Tarik and Bronowicki, Jean-Pierre and Lohse, Ansgar W and Müllhaupt, Beat and Schuchmann, Marcus and Bourlière, Marc and Buti, Maria and Roberts, Stuart K and Gane, Ed J and Stern, Jerry O and Vinisko, Richard and Kukolj, George and Gallivan, John-Paul and Böcher, Wulf-Otto and Mensa, Federico J
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 7, pp. 630 - 639
In this phase 2b study, an interferon-free regimen consisting of the combination of a protease inhibitor (faldaprevir), a nonnucleoside polymerase inhibitor... 
PROTEASE INHIBITOR | GENOTYPE-1-INFECTED SUBJECTS | ANTIVIRAL AGENTS | MEDICINE, GENERAL & INTERNAL | TELAPREVIR | C VIRUS-INFECTION | INTERFERON-FREE REGIMEN | INHIBITOR BI 207127 | RIBAVIRIN | COMBINATION | HEPATITIS-C | Enzyme Inhibitors - adverse effects | DNA-Directed RNA Polymerases - antagonists & inhibitors | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | Thiazoles - therapeutic use | Hepatitis C, Chronic - drug therapy | Oligopeptides - adverse effects | Enzyme Inhibitors - therapeutic use | Thiazoles - adverse effects | Viral Load | Oligopeptides - therapeutic use | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Adult | Female | Hepatitis C, Chronic - genetics | Protease Inhibitors - therapeutic use | Clinical trials | Antiviral agents | Research | Hepatitis C | Drug therapy | Photosensitivity | Diarrhea | Chronic infection | Nausea | Proteinase inhibitors | Patients | Ribavirin | Hepatitis | Vomiting | Human immunodeficiency virus--HIV | Interferon | Drug dosages | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke
by Ovbiagele, Bruce and Diener, Hans-Christophe and Yusuf, Salim and Martin, Reneé H and Cotton, Daniel and Vinisko, Richard and Donnan, Geoffrey A and Bath, Philip M and PROFESS Investigators, for the and PROFESS Investigators
JAMA, ISSN 0098-7484, 11/2011, Volume 306, Issue 19, pp. 2137 - 2144
CONTEXT Recurrent stroke prevention guidelines suggest that larger reductions in systolic blood pressure (SBP) are positively associated with a greater... 
TELMISARTAN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR OUTCOMES | TRANSIENT ISCHEMIC ATTACK | EXTENDED-RELEASE DIPYRIDAMOLE | COMBINATION | HEALTH-CARE PROFESSIONALS | PROGNOSTIC VALUE | ASSOCIATION | HYPERTENSIVE PATIENTS | SECONDARY PREVENTION | Blood Pressure | Recurrence | Benzoates - therapeutic use | Diastole | Follow-Up Studies | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Reference Values | Risk | Systole | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Female | Aspirin - therapeutic use | Stroke - mortality | Benzimidazoles - therapeutic use | Stroke - prevention & control | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Myocardial Infarction | Platelet Aggregation Inhibitors | Aged | Brain Ischemia - mortality | Dipyridamole - administration & dosage | Measurement | Stroke (Disease) | Causes of | Blood pressure | Methods | Medical records | Medical research | Stroke
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
by Lin, Nancy U and Winer, Eric P and Wheatley, Duncan and Carey, Lisa A and Houston, Stephen and Mendelson, David and Munster, Pamela and Frakes, Laurie and Kelly, Steve and Garcia, Agustin A and Cleator, Susan and Uttenreuther-Fischer, Martina and Jones, Hilary and Wind, Sven and Vinisko, Richard and Hickish, Tamas
Breast Cancer Research and Treatment, ISSN 0167-6806, 6/2012, Volume 133, Issue 3, pp. 1057 - 1065
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label,... 
Human epidermal growth factor receptor | Medicine & Public Health | ErbB2 | ErbB1 | Oncology | Breast cancer | Second-generation small molecule kinase inhibitors | Trastuzumab | LAPATINIB | GROWTH-FACTOR RECEPTOR | ONCOLOGY | EGFR/HER2 INHIBITOR | TYROSINE KINASE | RESISTANCE | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Disease Progression | Breast Neoplasms - metabolism | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Quinazolines - administration & dosage | Aged | Receptor, ErbB-2 - antagonists & inhibitors | Antimitotic agents | Medical research | Care and treatment | Cancer patients | Chemotherapy | Epidermal growth factor | Medicine, Experimental | Metastasis | Antineoplastic agents | Cancer | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
by Visvanathan, Sudha and Daniluk, Stefan and Ptaszyński, Rafał and Müller-Ladner, Ulf and Ramanujam, Meera and Rosenstock, Bernd and Eleftheraki, Anastasia G and Vinisko, Richard and Petříková, Alena and Kellner, Herbert and Dokoupilova, Eva and Kwiatkowska, Brygida and Alten, Rieke and Schwabe, Christian and Baum, Patrick and Joseph, David and Fine, Jay S and Padula, Steven J and Steffgen, Jürgen
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2019, Volume 78, Issue 6, pp. 754 - 760
ObjectiveTo evaluate the safety, efficacy and therapeutic mechanism of BI 655064, an antagonistic anti-CD40 monoclonal antibody, in patients with rheumatoid... 
SYSTEMIC-LUPUS-ERYTHEMATOSUS | INCREASED EXPRESSION | PHARMACOKINETICS | EFFICACY | SAFETY | INADEQUATE RESPONSE | CD40 LIGAND | RHEUMATOLOGY | INHIBITOR | T-CELLS | DISEASE-ACTIVITY | B-cells | Rheumatoid Arthritis | 1506 | autoantibodies | 2311
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab
by Visvanathan, Sudha and Baum, Patrick and Vinisko, Richard and Schmid, Ramona and Flack, Mary and Lalovic, Bojan and Kleiner, Oliver and Fuentes-Duculan, Judilyn and Garcet, Sandra and Davis, Justin W and Grebe, Kristie M and Fine, Jay S and Padula, Steven J and Krueger, James G
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 06/2019, Volume 143, Issue 6, pp. 2158 - 2169
IL-23 contributes to the activation, maintenance, and proliferation of T 17 cells and plays a major role in psoriasis pathophysiology. IL-23p19 inhibition with... 
ustekinumab | psoriasis | biomarkers | IL-17 | Risankizumab | IL-23 | IL-12 | Immunohistochemistry | Skin | Psoriasis | Dendritic cells | Analysis | Cell proliferation | Genes | Helper cells | Hispanic Americans | Interleukin 23 | Lymphocytes T | Gene sequencing | Histopathology | Lymphocytes | Skin diseases | Lesions | CD11c antigen | Cytokines | Lipocalin | Glycoprotein | Keratinocytes | Interleukin 12 | CD3 antigen | Ribonucleic acid--RNA | Gene expression | Patients | Studies | Monocytes | Biopsy | Biomarkers | Sampling methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir
by Berger, Kristi L and Sarrazin, Christoph and Nelson, David R and Scherer, Joseph and Sha, Nanshi and Marquis, Martin and Côté-Martin, Alexandra and Vinisko, Richard and Stern, Jerry O and Mensa, Federico J and Kukolj, George
PLoS ONE, ISSN 1932-6203, 08/2016, Volume 11, Issue 8, p. e0160668
Background & Aim The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We... 
PRECLINICAL CHARACTERIZATION | THERAPY | BI 207127 | VARIANTS | SOFOSBUVIR | MULTIDISCIPLINARY SCIENCES | INFECTION | RIBAVIRIN | INHIBITOR | HEPATITIS-C | BMS-791325 | Acrylates - therapeutic use | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Thiazoles - therapeutic use | Hepacivirus - metabolism | Oligopeptides - therapeutic use | Clinical Trials, Phase III as Topic | Protease Inhibitors - therapeutic use | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Mutation - genetics | Polymorphism, Genetic - drug effects | Carrier Proteins - genetics | Carrier Proteins - metabolism | Drug Resistance, Viral - drug effects | Polymorphism, Genetic - genetics | Viral Nonstructural Proteins - metabolism | Hepatitis C, Chronic - genetics | Viral Nonstructural Proteins - antagonists & inhibitors | Clinical Trials, Phase I as Topic | Amino Acid Substitution | Clinical Trials, Phase II as Topic | Antiviral agents | Complications and side effects | Drug resistance in microorganisms | Proteases | Physiological aspects | Dosage and administration | Genetic aspects | Research | Hepatitis C | Drug therapy | Clinical trials | Amino acids | Viruses | Infections | Ribavirin | Disease resistance | Hepatitis | Genotype & phenotype | Consolidation | Protease | Gastroenterology | Genotypes | Alanine | RNA polymerase | Patients | RNA-directed RNA polymerase | Studies | Polymerase | Inhibitors | Acids | Interferon | Hepatitis C virus | Binding sites | Polymorphism | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Types of Stroke Recurrence in Patients with Ischemic Stroke: A Substudy from the PRoFESS Trial
by Toni, Danilo and Di Angelantonio, Emanuele and Di Mascio, Maria Teresa and Vinisko, Richard and Bath, Philip MW and PRoFESS Study Grp and PRoFESS Study Group and for the PRoFESS Study Group
International Journal of Stroke, ISSN 1747-4930, 10/2014, Volume 9, Issue 7, pp. 873 - 878
Background Risk profiles for stroke recurrence are poorly characterized. Aims We determined the variation in the risk and type of recurrent stroke among index... 
predictors | recurrence | ischemic | risk factors | stroke | Recurrence | Stroke | Ischemic | Risk factors | Predictors | EVENTS | ASPIRIN | CLOPIDOGREL | RISK-FACTOR | CEREBRAL MICROBLEEDS | INTRACEREBRAL HEMORRHAGE | ATTACK | PERIPHERAL VASCULAR DISEASE | LACUNAR STROKE | Brain Ischemia - epidemiology | Stroke - prevention & control | Brain Ischemia - classification | Humans | Kaplan-Meier Estimate | Male | Risk | Brain Ischemia - prevention & control | Stroke - drug therapy | Secondary Prevention - methods | Stroke - classification | Brain Ischemia - drug therapy | Female | Stroke - epidemiology | Aged | Hypertension | Care and treatment | Aspirin | Relapse | Atrial fibrillation | Anticoagulants (Medicine) | Diseases | Stroke (Disease) | Ischemia | Analysis | Hypoglycemic agents | Stroke patients | Smoking
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Chronic pain syndromes after ischemic stroke: PRoFESS trial
by O'Donnell, Martin J and Diener, Hans-Christoph and Sacco, Ralph L and Panju, Akbar A and Vinisko, Richard and Yusuf, Salim and PRoFESS Investigators
Stroke, ISSN 0039-2499, 05/2013, Volume 44, Issue 5, pp. 1238 - 1243
Background and Purpose-Chronic pain syndromes are reported to be common after stroke, but most previous epidemiological studies have generally included small... 
epidemiology | pain | ischemic stroke | MEDICAL COMPLICATIONS | POPULATION | RISK-FACTORS | PREVALENCE | CLINICAL NEUROLOGY | LONG-TERM PAIN | PERIPHERAL VASCULAR DISEASE | QUALITY-OF-LIFE | RECURRENT STROKE | EXTENDED-RELEASE DIPYRIDAMOLE | SHOULDER PAIN | CENTRAL POSTSTROKE PAIN | Brain Ischemia - complications | Brain Ischemia - epidemiology | Severity of Illness Index | Follow-Up Studies | Stroke - psychology | Humans | Middle Aged | Risk Factors | Stroke - complications | Male | Neuropsychological Tests | Chronic Pain - epidemiology | Cognition Disorders - etiology | Brain Ischemia - psychology | Aged, 80 and over | Female | Stroke - epidemiology | Aged | Pain Measurement | Chronic Pain - etiology | Cognition Disorders - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
by Todd, JL and Neely, ML and Overton, R and Durham, K and Gulati, M and Huang, H and Roman, J and Newby, LK and Flaherty, KR and Vinisko, R and Liu, Y and Roy, J and Schmid, R and Strobel, B and Hesslinger, C and Leonard, TB and Noth, I and Belperio, JA and Palmer, SM and Asi, W and Baker, A and Beegle, S and Condos, R and Cordova, F and Culver, DA and de Andrade, JAM and Dilling, D and Glassberg, M and Guntupalli, K and Gupta, N and Case, AH and Hotchkin, D and Huie, T and Kaner, R and Kim, H and Kreider, M and Lancaster, L and Lasky, J and Lederer, D and Lee, D and Liesching, T and Lipchik, R and Lobo, J and Mageto, Y and Menon, P and Morrison, L and Namen, A and Oldham, J and Raj, R and Ramaswamy, M and Russell, T and Sachs, P and Safdar, Z and Sigal, B and Silhan, L and Strek, M and Suliman, S and Tabak, J and Walia, R and Whelan, TP and IPF-PRO Registry Investigators and on behalf of the IPF-PRO Registry investigators
RESPIRATORY RESEARCH, ISSN 1465-993X, 10/2019, Volume 20, Issue 1, pp. 1 - 13
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which diagnosis and management remain challenging. Defining the circulating... 
LUNG | DIAGNOSIS | Observational study | Interstitial lung diseases | RESPIRATORY SYSTEM | DISEASE | TISSUE | Proteome | Registries | SARCOIDOSIS | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Obesity and recurrent vascular risk after a recent ischemic stroke
by Ovbiagele, Bruce and Bath, Philip M and Cotton, Daniel and Vinisko, Richard and Diener, Hans-Christoph
Stroke, ISSN 0039-2499, 12/2011, Volume 42, Issue 12, pp. 3397 - 3402
Background and Purpose-Although obesity is an established risk factor for the occurrence of a primary stroke, little is known about the impact of baseline... 
Myocardial infarction | Body mass index | Obesity | Paradox | Prognosis | Recurrent stroke | Outcomes | Vascular death | Overweight | METABOLIC SYNDROME | vascular death | body mass index | myocardial infarction | PREVENTION | prognosis | CLINICAL NEUROLOGY | TELMISARTAN | IMPACT | CLOPIDOGREL | recurrent stroke | outcomes | paradox | BODY-MASS INDEX | PERIPHERAL VASCULAR DISEASE | EXTENDED-RELEASE DIPYRIDAMOLE | OF-NEUROLOGY AFFIRMS | WEIGHT | overweight | obesity | Brain Ischemia - complications | Brain Ischemia - epidemiology | Cardiovascular Diseases - etiology | Recurrence | Obesity - complications | Humans | Middle Aged | Risk Factors | Stroke - complications | Male | Risk | Obesity - epidemiology | Cardiovascular Diseases - epidemiology | Female | Stroke - epidemiology | Aged | Databases, Factual
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
by Stadler, Walter M and Vaughn, David J and Sonpavde, Guru and Vogelzang, Nicholas J and Tagawa, Scott T and Petrylak, Daniel P and Rosen, Peter and Lin, Chia‐Chi and Mahoney, John and Modi, Sanjiv and Lee, Peter and Ernstoff, Marc S and Su, Wu‐Chou and Spira, Alexander and Pilz, Korinna and Vinisko, Richard and Schloss, Charles and Fritsch, Holger and Zhao, Charles and Carducci, Michael A
Cancer, ISSN 0008-543X, 04/2014, Volume 120, Issue 7, pp. 976 - 982
BACKGROUND Polo‐like kinases (Plks) control multiple steps during the cell cycle, and Plk1 is overexpressed in urothelial cancer (UC). Volasertib (BI 6727), a... 
phase 2 trial | volasertib | urothelial cancer | polo‐like kinase inhibitor | polo-like kinase inhibitor | Protein Kinase Inhibitors - pharmacokinetics | Urologic Neoplasms - metabolism | Pteridines - therapeutic use | Humans | Middle Aged | Male | Pteridines - pharmacokinetics | Treatment Outcome | Antineoplastic Agents - therapeutic use | Disease-Free Survival | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Aged, 80 and over | Female | Aged | Antineoplastic Agents - pharmacokinetics | Urologic Neoplasms - enzymology | Evaluation | Influence | Phosphotransferases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study
by Visvanathan, Sudha and Visvanathan, Sudha and Baum, Patrick and Baum, Patrick and Salas, Azucena and Vinisko, Richard and Schmid, Ramona and Schmid, Ramona and Grebe, Kristie M and Grebe, Kristie M and Davis, Justin W and Davis, Justin W and Wallace, Kori and Wallace, Kori and Böcher, Wulf O and Böcher, Wulf O and Padula, Steven J and Padula, Steven J and Fine, Jay S and Panés, Julián and Panés, Julián
Journal of Crohn's & colitis, ISSN 1873-9946, 2018, Volume 12, Issue 10, pp. 1170 - 1179
Background and Aims: We aimed to investigate the underlying mechanism of action of risankizumab, a monoclonal antibody targeting the IL-23 p19 subunit,... 
Biomarkers | Clinical trials | Endoscopy | INFLAMMATORY-BOWEL-DISEASE | biomarkers | DOUBLE-BLIND | endoscopy | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | TH17 CELLS | Biopsy - methods | Ileum - pathology | Interleukin-23 Subunit p19 - antagonists & inhibitors | Gene Expression - drug effects | Humans | Immunosuppressive Agents - pharmacokinetics | Middle Aged | Colon - drug effects | Interleukin-17 - immunology | Colon - immunology | Male | Drug Monitoring - methods | Ileum - immunology | Ileum - drug effects | Crohn Disease - diagnosis | Adult | Female | Immunosuppressive Agents - administration & dosage | Double-Blind Method | Colon - pathology | Antibodies, Monoclonal - pharmacokinetics | Gene Expression Profiling - methods | Crohn Disease - immunology | Remission Induction | Endoscopy, Digestive System - methods | Monitoring, Immunologic - methods | Patient Acuity | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Interleukin-23 Subunit p19 - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker parameters in patients with active rheumatoid arthritis: A randomised, double-blind, placebo-controlled, phase IIa study
by Visvanathan, Sudha and Daniluk, Stefan and Ptaszylski, Rafal and Müller-Ladner, Ulf and Ramanujam, Meera and Rosenstock, Bernd and Eleftheraki, Anastasia G and Vinisko, Richard and Petíková, Alena and Kellner, Herbert and Dokoupilova, Eva and Kwiatkowska, Brygida and Alten, Rieke and Schwabe, Christian and Baum, Patrick and Joseph, David and Fine, Jay S and Padula, Steven J and Steffgen, Jürgen
Annals of the Rheumatic Diseases, ISSN 0003-4967, 2019
B-cells | autoantibodies | rheumatoid arthritis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV
by Dieterich, Douglas and Nelson, Mark and Soriano, Vicente and Arastéh, Keikawus and Guardiola, Josep M and Rockstroh, Jürgen K and Bhagani, Sanjay and Laguno, Montserrat and Tural, Cristina and Ingiliz, Patrick and Jain, Mamta K and Stern, Jerry O and Manero, Montserrat and Vinisko, Richard and Kort, Jens and STARTVerso4 study group
AIDS, ISSN 0269-9370, 03/2015, Volume 29, Issue 5, pp. 571 - 581
OBJECTIVE:Faldaprevir is a potent, once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor. STARTVerso4 assessed the efficacy and safety of faldaprevir... 
SVR12 | faldaprevir | NS3/4A protease inhibitor | HIV | hepatitis C virus genotype 1 | Recombinant Proteins - therapeutic use | Viremia - diagnosis | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Thiazoles - therapeutic use | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Young Adult | Drug Therapy, Combination - methods | Adolescent | HIV Infections - complications | Adult | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers
by Huang, Fenglei and Scholl, Paul and Huang, David B and MacGregor, Thomas R and Vinisko, Richard and Castles, Mark A and Berger, Frank and Robinson, Patrick
The Journal of Clinical Pharmacology, ISSN 0091-2700, 07/2011, Volume 51, Issue 7, pp. 1061 - 1070
The objective of this investigation was to evaluate the pharmacokinetic interaction of lopinavir/ritonavir (LPV/r) with BILR 355. In group A, 26 healthy... 
lopinavir | HIV | drug‐drug interaction | BILR 355 | ritonavir | nonnucleoside reverse transcriptase inhibitor | P‐glycoprotein | protease inhibitor (PI) | P-glycoprotein | drug-drug interaction | IMMUNODEFICIENCY-VIRUS-INFECTION | SAFETY | HIV-1-INFECTED PATIENTS | PROTEASE INHIBITOR | HEPATIC CYP3A | HIV-INFECTION | THERAPY | RESISTANCE | ANTIVIRAL ACTIVITY | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | Reverse Transcriptase Inhibitors - blood | Humans | Middle Aged | Half-Life | Pyridines - pharmacokinetics | Biological Availability | Male | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Pyridines - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Azepines - adverse effects | Ritonavir - administration & dosage | Ritonavir - blood | Lopinavir | Pyrimidinones - adverse effects | Azepines - blood | HIV Protease Inhibitors - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Pyrimidinones - blood | Azepines - pharmacokinetics | Pyrimidinones - administration & dosage | Ritonavir | Drug interactions | Physiological aspects | Dosage and administration | Reverse transcriptase inhibitors | Research | Bioavailability | Protease inhibitors | Drug dosages | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights